Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

SUNNYVALE, Calif., May 1, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its three months ended March 31, 2013.

Financial Results for the Three Months Ended March 31, 2013 Non-GAAP net loss reported for the quarter ended March 31, 2013 was $28.3 million, or $0.40 loss per share compared to non-GAAP net loss of $9.3 million, or $0.14 loss per share for the quarter ended March 31, 2012.  See "Use of Non-GAAP Financial Measures" below for a description of our non-GAAP measures. Reconciliation between certain GAAP and non-GAAP measures is provided at the end of this press release.

As reported on April 11, 2013, the Company earned a $50 million milestone payment obligation under its collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. and its affiliates ("Janssen") as a result of the enrollment of a fifth patient in a study using ibrutinib (PCI-32765) as a monotherapy versus chlorambucil in elderly patients with newly diagnosed chronic lymphocytic lymphoma/small lymphocytic lymphoma. The $28.3 million non-GAAP net loss for the quarter ended March 31, 2013 did not include the $50 million milestone earned on April 11, 2013. The Company will record the above milestone as revenue for the quarter ending June 30, 2013. As such, the Company expects non-GAAP net income/loss to be near break-even for the quarter ending June 30, 2013 and also for the full year ending December 31, 2013. This includes the assumption of costs by Janssen in excess of the $50 million annual cap per calendar year ("Excess Amounts") under the Agreement with Janssen.

The generally accepted accounting principles ("GAAP") net loss for the quarter ended March 31, 2013 was $51.9 million, or $0.73 loss per share. This includes stock-based compensation expense of $23.6 million. For the quar
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
11. Hospira Reports First-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Texas , Sept. 17, 2014  Lightbeam ... Direct Accountable Care Organization (Physician Direct ACO) to ... their physicians in providing better care while reducing ... Physician Direct Accountable Care Organization ... Network Services (OPNS). The OPNS mission is to ...
(Date:9/17/2014)... -- An analysis done by the CVS Health Research ... new and expensive treatment for Hepatitis C introduced in ... months (May through August 2014) there has been a ... suggests another surge of patients will begin therapy when ... and shorter duration are introduced in the Fall. ...
(Date:9/17/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... public offering of 4,500,000 shares of its common stock at ... share. Aratana has granted the underwriters a 30-day ... shares of its common stock. Jefferies ...
Breaking Medicine Technology:Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2
... Synteract, Inc ., a full-service contract ... training classes for CDISC , a global, ... the acquisition, exchange, submission and archive of clinical ... 21-24, 2012 at Synteract,s Carlsbad, Calif., headquarters. ...
... COLUMBUS, Ohio, Feb. 17, 2012  Chemical Abstracts Service ... Taylor & Francis, a leading publisher of scientific ... new experimental procedures for chemical reactions from three ... SciFinder®. (Logo: http://photos.prnewswire.com/prnh/20110418/MM84805 ) ...
Cached Medicine Technology:Synteract Hosting CDISC Classes on Regulatory Data Standards, Feb. 21-24, in California 2CAS and Taylor & Francis Collaborate to Improve Scientists' Access to Published Research 2
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 North ... were recently granted several awards for their top-notch services. ... patient experience, orthopedic care and GYN surgery. , Hospital-wide, ... Safety Excellence Award™. They have received this award for ... among the top 5 percent in the nation for ...
(Date:9/17/2014)... (HealthDay News) -- A blood test that measures DNA ... a better assessment of the state of a man,s ... routinely, this blood test could reveal when treatment ... promoting tumor growth, the researchers suggested. "Our study ... advanced prostate cancer and often initially very effective started ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... Why are Asian Americans at higher risk of developing ... develop the disease at lower body weights? One part ... traditional high-fiber, low-fat Asian diets to current westernized diets, ... heritage, says George King, M.D., Senior Vice President and ... senior author of the study. , A Joslin randomized ...
(Date:9/17/2014)... The in vitro diagnostics (IVD) marketplace is ... on molecular diagnostics for conditions such as infectious diseases, ... IVD market value is projected to be worth around ... major drivers of the market’s growth include the shift ... by the explosion for raid and minimally-invasive diagnostic tools; ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... countrymen safe drinking water within a matter of four ... // to make this possible. Most people living in ... water. ,Inaugurating a conference of ministers ... sanitation in states and union territories, the prime minister ...
... speak hundred words, these non-verbal communications is also found ... been a major cause of distress and may lead ... School of Medicine along with his colleagues from Indianapolis ... as reported in the Journal of General Internal Medicine ...
... Journal of the American Medical Association has published that ... continue their anti-depressant medication to avoid a relapse.// ... University and Massachusetts General Hospital, where 201 pregnant women ... not depressed during the course of the study. According ...
... Michael Horwin have launched the SV40 Cancer Foundation in ... 1999 from an SV40 positive brain tumor. // The ... encourage independent research and to facilitate clinical improvements." ... brain tumor that was caused by an active SV40 ...
... there is a definite link between disease and higher death rates ... the // data of 1,347 people aged about 56 in the ... ,The IQ of the volunteers was assessed by a written test ... scores follow a social trend and that the poorest socioeconomic groups ...
... revealed that a Husband’s comforting touch can be a ... the study, those who establish instant communication by reaching ... A handy tip on how human touch can alleviate ... feature of the study revealed that relief from a ...
Cached Medicine News:Health News:Safe Drinking Water To Be Made Available 2Health News:Pregnancy Not An Antidote To Depression 2Health News:Handy Touch - A Wand to Bust Stressful Situations 2
... Nebulizer Disposable Prefilled 28%-100% FIO 2 1000ML ... ,Our prefilled nebulizers provide unmatched performance and ease ... high-output aerosols adjustable from 28% to 100% FIO ... solutions: sterile water for inhalation, USP; 0.45% sodium ...
Respirgard II Nebulizer System with Acorn II Nebulizer, 7' (2 m) supply tubing, universal "antidrool" tee, mouthpiece, 6" (15 cm) aerosol tube, wye, one-way valve and expiratory filter...
... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
... modified nebulizer setups to deliver CNT and ... your patient is critical? OMNI~MAX has everything ... Heliox rescue therapy. In severe obstructive disease, ... of care in hospitals across the nation. ...
Medicine Products: